1. Minichiello T, Fogarty PF. Diagnosis and management of venous thromboembolism. Med Clin North Am. 2008;92:443-465.
2. Deitcher SR, Carman TL. Deep venous thrombosis and pulmonary embolism. Curr Treat Options Cardiovasc Med. 2002;4:223-238.
3. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):454S-545S.
4. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):160S-198S.
5. Bussey HL, Wittkowsky AK, Hylek EM, et al. Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy. 2008;28:141-143.
6. McWilliam A, Lutter R, Nardinelli C. Health care savings from personalizing medicine using genetic testing: the case of warfarin. American Enterprise Institute-Brookings Joint Center for Regulatory Studies. November 2006. Available at: www.reg-markets.org/publications/abstract.php?pid=1127&printversion=1. Accessed October 2, 2010.
7. Coumadin [package insert]. Princeton, NJ. Bristol-Myers Squibb; 2010.
8. Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ. 2007;177:369-371.
9. Holmes DR, Kereiakes DJ, Kleiman NS, et al. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol. 2009;54:95-109.
10. Hermosillo AJ, Spinler SA. Aspirin, clopidogrel and warfarin: Is the combination appropriate and effective or inappropriate and too dangerous? Ann Pharmacother. 2008;42:790-805.
11. Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):776S-814S.
12. Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol. 2006;18:162-164.
13. Bauer KA. New anticoagulants. Hematology Am Soc Hematol Educ Program. 2006;450-456.
14. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular weight heparin and warfarin for the treatment of deep vein thrombosis. JAMA. 2005;293:681-689.
15. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
16. The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate versus the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.
17. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185.
18. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement. Lancet. 2007;370:949-956.
19. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Re-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
20. Hughes S. RECORD 1, 2 and 3 rivaroxaban trials published. Heartwire July 1, 2008. Available at: http://www.theheart.org/article/878097.do. Accessed November 24, 2008.
21. Fragmin [package insert]. Woodcliff Lake, NJ: Eisai; 2010.
22. Lovenox [package insert]. Greenville, NC: Sanofi-Aventis; 2009.
23. Innohep [package insert] Parsippany, NJ: LEO Pharmaceuticals Products; 2010.
24. Arixtra [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2010.
